Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 13/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.39 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6074494 | 0.81 | ADAMTS5 (0.43) | ADAMTS5ADAMTS4ADAM17ADAM10MMP12 | |
| SCHEMBL6074524 | 0.74 | MAPT (0.57) | HRH3 | |
| SCHEMBL6704329 | 0.74 | PPARG (0.44) | ADAMTS5ADAMTS4ADAM17ADAM10MMP12 | |
| SCHEMBL5062730 | 0.72 | CXCR4 (0.42) | ADAMTS5ADAMTS4MMP2HDAC8CXCR4 | |
| SCHEMBL28722955 | 0.72 | CXCR4 (0.53) | HDAC8CXCR4 | |
| SCHEMBL8402315 | 0.72 | GAA (0.42) | MMP2HDAC8CXCR4 | |
| SCHEMBL3156973 | 0.72 | MAPT (0.50) | HDAC8CXCR4 | |
| SCHEMBL1012031 | 0.72 | CXCR4 (0.53) | HDAC8CXCR4 | |
| SCHEMBL5306952 | 0.72 | CXCR4 (0.42) | HDAC8HRH3CXCR4 | |
| SCHEMBL5182408 | 0.72 | THRA (0.43) | ADAMTS5ADAMTS4HDAC8HRH3CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| EP-1301482-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
| WO-2002006232-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADAMTS5 3757/4885ADAMTS4 4268/4885ADAM17 4831/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADAMTS5 3757/4885ADAMTS4 4268/4885ADAM17 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.